RBRC00193, GRS.Cg-Tnc<tm1Sia>/Rbrc

RBRC No. RBRC00193
Type Targeted MutationCartagena ♀
Species Mus musculus
Strain name GRS.Cg-Tnc<tm1Sia>/Rbrc
Former Common name GRS/A-TgH(Tnc), GR-TNKO
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Donor strain B6.CB-Tnctm1
Background strain GRS/A
Appearance
1 Appearance albino
Genotype a/a, c/c
Strain development The original tenascin deficient mice with mixed genetic background was reported to develop normally without tenascin. To clarify the biological function of tenascin-C in vivo, several congenic strains with inbred background have been developed by Dr. Kusakabe M, Cell Biology Laboratory, Life Science Tsukuba Research Center, RIKEN since 1992.
The tenascin-deficient congenic strains were thus developed by successive backcrossing into A, BALB/cA, C57BL/6N, C3H/HeN, and GRS/A.
Strain description This strain is useful to study the biological function of extracellular matrix tenascin-C in vivo, espacially in the field of tumor development, tumor metastasis, wound healing, tissue regeneration, angiogenesis, tissue interaction etc. Background strain, GRS/A have a high incidence of mammary tumours which are highly hormone-responsive in breeding females.
Health Report No Data
Gene Details
Promoter No Data
1 Symbol Tnc
Symbol name tenascin C
Chromosome 4
Common name Tnc; tenascin C, Hxb, Ten, TN-C, AI528729
Symbol description No Data
2 Symbol lacZ
Symbol name beta-galactosidase (E. coli)
Chromosome 4
Common name No Data
Symbol description E. coli beta galactosidase
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
3 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 4
Common name neo; neomycin;
Symbol description No Data
References Am J Pathol. 1998 May;152(5):1237-45.
Biochem Biophys Res Commun. 1996 Apr 5;221(1):151-6.
Biochem Biophys Res Commun. 1997 Feb 13;231(2):356-9.
Biochem Biophys Res Commun. 2002 Feb 1;290(4):1220-7.
Exp Mol Pathol. 2002 Jun;72(3):186-95.
Gene. 1991 Aug 15;104(2):177-85.
Genes Dev. 1992 Oct;6(10):1821-31.
Invest Ophthalmol Vis Sci. 1999 May;40(6):1071-80.
J Comp Neurol. 2001 Feb 19;430(4):485-500.
J Invest Dermatol. 1998 Dec;111(6):930-5.
J Neurosci. 1995 Mar;15(3 Pt 1):1971-83.
Perspect Dev Neurobiol 1994;2(1):111-16.

Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Research applications No Data
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Am. J. Pathol., 152, 1237-1245 (1998). J. Invest. Dermatol., 111, 930-935 (1998). Invest. Ophthalmol. Visual. Sci., 40, 1071-1080 (1999).
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor RIKEN, BioResource Center
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months